Calypte Biomedical Approved for Listing on AMEX: HIV
16 Agosto 2004 - 10:22AM
PR Newswire (US)
Calypte Biomedical Approved for Listing on AMEX: HIV Trading
Expected to Begin Wednesday August 18th PLEASANTON, Calif., Aug. 16
/PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC:CYPT)
(BULLETIN BOARD: CYPT) today announced that its common stock has
been approved for listing on the American Stock Exchange ("Amex").
Calypte's common stock is expected to commence trading on the Amex
under the symbol "HIV" on Wednesday, August 18, 2004. "Calypte's
listing on the Amex is another significant objective in the
progress of our company," said Anthony Cataldo, Chairman of
Calypte. "The listing provides greater visibility for Calypte and a
listing with Amex eliminates certain restrictions inherent in being
traded on the OTC Bulletin Board. Often these restrictions limit
certain brokers and institutions in their ability to trade bulletin
board stocks." Calypte, under the symbol "CYPT" is expected to stop
trading on the OTC Bulletin Board at the close of business, August
17, 2004 and is expected to commence trading on the Amex on
Wednesday, August 18, 2004 under the symbol "HIV". About Calypte
Biomedical: Calypte Biomedical Corporation, headquartered in
Pleasanton, California, is a public healthcare company dedicated to
the development and commercialization of in vitro diagnostic tests,
primarily for the detection of antibodies to Human Immunodeficiency
Virus (HIV), and other sexually transmitted and infectious
diseases. Calypte's currently marketed laboratory-based tests
include an enzyme immunoassay (EIA) HIV-1 antibody screening test
and an HIV-1 antibody western blot supplemental test, the only two
FDA-approved HIV-1 antibody tests for use on urine samples, as well
as an FDA-approved serum HIV-1 antibody western blot supplemental
test. Calypte is actively engaged in developing new test products
for the rapid detection of HIV and other infectious diseases.
Calypte believes that there is a significant need for rapid
detection of such diseases globally to control their proliferation,
particularly in lesser-developed countries, which lack the medical
infrastructure to support laboratory-based testing. Calypte
believes that testing for HIV and other infectious diseases may
make important contributions to public health. Statements in this
press release that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent,
belief or current expectations of the Company and its management.
Such statements reflect management's current views, are based on
certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the
above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors,
including, but not limited to, the Company's ability to obtain
additional financing, demand for the Company's products, the
Company's success in designing and developing products, the
Company's research and development costs, the length of development
and product acceptance cycles, the amount that the Company invests
in new business opportunities and the timing of those investments,
competition, the degree to which the Company enters into commercial
agreements and strategic transactions and maintains and develops
commercial relationships, foreign exchange risks, world events,
international growth and expansion and changes in laws and
regulations. The Company undertakes no obligation to publicly
update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any
change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated
events. Factors that may impact the Company's success are more
fully disclosed in the Company's most recent public filings with
the U.S. Securities and Exchange Commission ("SEC"), including its
annual report on Form 10-KSB for the year ended December 31, 2003
and its subsequent filings with the SEC. Company Contact: Investor
Relations Contact: Richard Brounstein, CFO Tim Clemensen, (925)
730-7200 Rubenstein Investor Relations email: Phone: 212-843-9337
Email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Richard
Brounstein, CFO of +1-925-730-7200, ; Investor Relations - Tim
Clemensen, of Rubenstein Investor Relations, +1-212-843-9337, , for
Calypte Biomedical Corporation Web site: http://www.calypte.com/
Copyright